Tags Posts tagged with "Medical Marijuana"

Medical Marijuana

1 2536

Biotech Buzz Could Focus On Cannabis

San Francisco will be a hotbed for biotechnology this week. The annual JPMorgan Healthcare Conference kicks off on Monday the 9th and goes through Thursday the 12th. But this isn’t the only conference and there will surely be thousands of investors in the city to attend all kinds of presentations being made, which are focused on biotechnology & healthcare. Outside of just JPM’s conference, the crowd around Union Square also consists of the Biotech Showcase, which sets up at the Hilton San Francisco Union Square; and the OneMedForum across Post Street from the St. Francis.

Biotech_Showcase

There’s also the StartUp Health Festival on Montgomery Street and other conferences. Considering that thousands of people who aren’t going to invitation-only conferences like JPM, it would stand to reason that attention will be on the industry in full force this week.

Recently Vitality Biopharma (VBIO) announced that it would be presenting at the Biotech Showcase on Wednesday January 11th. The Showcase hosts over 2,800 attendees, over 5,600 one-on-one meetings, and will be expecting to see over 550 investors present.

Biotech Showcase™ is an investor and networking conference working to provide private and public biotech and life sciences companies with an opportunity to present to, and engage with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this week, which is widely viewed as setting the tone for the coming year…so JPMorgan is just the tip of the iceberg during San Fran’s biotech invasion.

“Biotech has historically outperformed the broader market during The J.P. Morgan Healthcare Conference,” biotech analysts at the firm wrote in a note to clients ahead of the event.

And we aren’t the only ones who could be seeing the potential “writing on the wall.” One of the presenters at the conference has even said, “…there’s a growing interest in medical cannabis among traditional health care institutions. This is a growing part of what is becoming mainstream health care.” As we said last week, even though we focus specifically on marijuana stocks, the biotech aspect of VBIO could be something to pay attention to heading into this week, considering the historic impact that the JPM conference (starts today) has had in the past for companies that have a stake in the space.

We said that this week could shed some light on many biotech companies including those involved with cannabis. Now we see that VBIO will be at ground zero, not just as another biotech company that could benefit from the shockwave but management will be in the exact location and presenting to the exact audiences.

Company CEO Robert Brooke will provide a 30-minute overview of Vitality Biopharma’s business during his presentation and will be available to participate in one-on-one meetings with registered attendees.

Event: Biotech Showcase Conference
Date: Wednesday, January 11, 2017
Time: 8:00 a.m. PT
Track: Room 8 (Ballroom Level)
Location: Hilton San Francisco Union Square, San Francisco, CA


 

 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 5569

Vitality Biopharma Receives DEA Approval for Cannabinoid Pharma Development Facility

Approval of cannaboside pharmaceutical research included review by FDA and California Research Advisory Panel

LOS ANGELES, CA–(Marketwired – Dec 21, 2016) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has received approval from both the U.S. Drug Enforcement Agency (DEA) and the State of California Research Advisory Panel which permits the Company to scale up activities at its facilities used for the development of novel cannabinoid pharmaceutical prodrugs.

Vitality has been working with the DEA to ensure adequate on-site measures are in place to prevent diversion of Schedule I controlled substances. As a component of this process, Vitality’s preclinical studies for its proprietary prodrugs of CBD and THC were reviewed and approved by the U.S. Food & Drug Administration (FDA). The California Research Advisory Panel, a part of the California Attorney General’s Office, has also granted Vitality a research permit to conduct cannabinoid pharmaceutical development activities that are designed to enable regulatory approval of first-in-man clinical trials.

Despite cannabis attaining legal status within the State of California and in many other states across the U.S. for medical and recreational purposes, pharmaceutical research and development continues to be closely regulated by the DEA and FDA. Vitality’s work is focused on developing a novel class of THC and CBD prodrugs that reduce or avoid psychoactive side effects through targeted prodrug technology.

“We are excited to scale up our research and to aggressively pursue clinical testing of our compounds, and this approval greenlights that work,” said Dr. Brandon Zipp, Director of R&D, and Scientific Co-founder of Vitality Biopharma. Robert Brooke, the Company’s CEO, further states that, “There are surprisingly few companies in the United States that are properly licensed and developing differentiated cannabinoid pharmaceutical products. We are very proud of our team’s work to enable this milestone, and believe that recent discoveries have provided us with a very unique opportunity.”

About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

CONTACT INFORMATION
Contact
Vitality Biopharma
Investor Relations
info@vitality.bio
1-530-231-7800
www.vitality.bio

 

 


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO), which we purchased in the open market. We plan to sell the “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

    0 3502

    Dr. Danial Schecter is the Co-Owner and  brainchild behind “Cannabinoid Medical Clinic”, a superchain series of clinics that specializes in the niche of assessing the prescription of cannabinoid-based medicinal treatments to patients that are referred only, no exceptions. There are currently ten clinics at the moment operating across Canada, from bustling Toronto to windy Edmonton. The expansion is on, as Canabo Medical recently went public on the Toronto Stock Exchange (Venture). As far as Dr. Schecter is concerned, it wouldn’t be a far fetched thing to say if I called him the encyclopedia of medicinal marijuana.

    He first learned about cannabinoid medicine at the University of Montreal. He trained shoulder-to-shoulder with some of the brightest academias in the field of medicinal marijuana in Canada. Therefore, I also come to the conclusion, that it would be just right to call him an expert in this field.

    It’s not just about his background, but the positive results he’s clocking in for Cannabinoid Medical Clinics.  As for business? It’s booming. Dr. Danial highlighted in an interview to lift that he on average sees 6 new patients and 18 follow ups on a regular day. Take into account the consultation fees for all 10 operating clinics and incoming clinics nationwide across Canada, with the patient number and follow up in mind, things are looking good for senior management. That very senior management is set to exploit an untapped niche in Canada. The reason why I say untapped is based on real life lessons. We have a lot of clinics here in Toronto. Approximately 90%, or probably even more, are your typical back-door, approve everyone type alternative therapy advisers or whatever. They’re normally given a mandate to approve all. I know because I have tested a lot of dispensaries and clinics alike here in Toronto. Canabo truly sets itself apart by underlining itself as a legitimate player due to two primary factors: the fact that appointments are reference based only through a family doctor or practicioner (unlike most others here in Toronto where only profits matter) and the simple fact that it doesn’t sell the product. These two ingredients indicate a priority given to what the boys on the block like to call, ‘Big Data.’

    Big Data, eh? Some people are discrediting Dr. Schecter’s vast experience by pinning the data collection and compliance side of what Canabo is doing for the cannabis industry as something of a lie. Chris Parry called this out for what it is on Twitter, as something of a deliberate wrongdoing. I agree with him because Dr. Schecter and his team aren’t a bunch of marketers trying to sell early data and make quick profits as some would like to suggest is with the case is with most venture listed firms, though that is nothing but bullshit. They have set the bar high to focus and carve a big share in the data collection side of cannabis.

    All you need to do to be convinced is simply understand the process of how the clinics operate. Remember, I have always preached simplicity when it comes to investment thesis and market psychology, and perhaps you should too. All it really takes is just a matter if due diligence. Dr. Schecter, in his interview to lift, stated, “I spend a minimum of 50 minutes with each new patient to understand what their past medical history is, what their main complaints and impairments are, what they have tried and failed in the past and understand what they are hoping to achieve by coming to the clinic.” Now that you’re a bit familiarized with the process, then you can easily answer for yourself whether Canabo is big data or not.

    This data can be utilized by Canabo itself through very simple, yet lucrative solutions to important strain related questions. Leafly is a great startup, don’t get me wrong, but Canabo will have the sort of demographics, results, and information that the government and licensed producers probably can’t wait to get their hands on. Oh, I totally forgot. This data will also have answers to question Leafy won’t have, like which strain is best for which age group. That’s fucking cool.

    Of course, I haven’t really gone over all of what Canabo offers because Chris Parry has already done that job. 

    This is a link to Chris Parry’s article on CMM.VN (listed on the TSXV): http://www.equity.guru/2016/11/28/canabo-medical-v-cmm-a-cannabis-business-model-thats-already-far-bigger-than-you-know/

    Click Here For Full Corporate Information

     

    ~ written by Hamzah Khan 


    Pursuant to an agreement between MAPH and Canabo Medical Corp (CMM), we were hired for a period beginning November 14 2016 and ending December 14, 2016 to publicly disseminate information about (CMM) including on the Website and other media including Facebook and Twitter. We are being paid $15,000 (CASH) for or were paid “0” shares of restricted common shares. We may buy or sell additional shares of (CMM)in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please refer to full disclaimer for more information

    0 4633

    Arcturus Establishes a New 420AppGaming Division Entering the $37 Billion Dollar Mobile Gaming Market

    VANCOUVER, British Columbia, October 13, 2016 /PRNewswire/ —

    Arcturus Growthstar Technologies Inc. (the “Company” or “Arcturus”) (CSE:AGS) (OTC Pink: AGSTF) is pleased to announce that it has established a new mobile gaming division (www.420AppGaming.com) with the intent to put out 420 themed games, which will generate revenue through In App Purchases (IAP) as well as through ad impressions. According to the Global Games Market Report, gamers worldwide will generate a total of $99.6 billion in revenues in 2016, up 8.5% compared to 2015. For the first time, mobile gaming will take a larger share than personal computers with $36.9 billion, up 21.3% globally.

    “With our recent mobile app acquisition and our growing focus on Cannabis, we feel Arcturus is now uniquely positioned to capitalize on these two huge and converging trends by publishing a suite of 420 themed games and utility apps,” says Mr. William Gildea, Arcturus Growthstar Technologies Inc.’s CEO and Chairman.

    Arcturus’ mobile app plan is to first launch a series of 420 themed casual games like Slots, Poker, Solitaire and Bingo, which all have a large and broad appeal, before year end 2016. According to ThinkGaming, five of the top 20 grossing revenue games are slots games while the rest are tried and true games that have proven to be winners on mobile devices and consistently in the top charts.

    “We are excited to be working with the Arcturus team and, in addition to the 420 gaming apps we are currently developing, in Q1 2017 we are also planning to release utility apps to compete with the biggest apps in the Cannabis space, including Weedmaps and Massroots,” says Mikael Hovhannisyan, the app development team manager.

    For further information, contact William Gildea, Director, at 617.834.9467.

    On behalf of the Board,

    Arcturus Growthstar Technologies Inc.

    William Gildea, CEO & Chairman

    About Arcturus

    The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Arcturus provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land. The contained system provides many other benefits including seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

    The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com which caters to B2B customers is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com which caters to both large and small agriculture green houses and controlled cultivation centers.

    Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts
    responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

    This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

    Contact:

    William Gildea
    CEO & Chairman
    +1-617-834-9467

    Arcturus Growthstar Technologies Inc.
    #5-9079 Shaughnessy Street
    Vancouver BC
    V6P 6R9

    0 739

    Could having a recreational marijuana program hurt the medical marijuana community? An analyst from GreenWave Advisors is under the impression that legalized retail marijuana will disturb the emerging medical sector. For the states that have legalized recreational marijuana, the number of medical marijuana patients has dropped. It was long speculated that many individuals who just wanted to smoke pot stated they have a medical condition such as chronic pain in order to legally buy and use marijuana.

    Having some form of Chronic discomfort or pain is generally the most common qualifying condition and this is the group that drops in patient counts when retail marijuana becomes available The analysts’ report highlights that the amount of patient decelerated in Colorado, Oregon and Washington D.C. Washington state does not count patients and Alaska patients can grow their medicine at home making it more difficult to keep count.

    GreenWave wrote, “Though Arizona permits only medicinal use, new cardholder applications were down sharply in May, perhaps in anticipation of a favorable election outcome for recreational use.” Another data point that supports the idea that some chronic pain sufferers are really retail customers is that medical marijuana spending patterns follow retail purchase habits.

    Sales among recreational marijuana users spike during the holiday season in December, summer and the classic 420 celebrations. This isn’t to imply that all patients who suffer from pain are really retail customers, although it does suggest that the medical market could be smaller than previously thought.

    The GreenWave report also indicates that as long as the DEA leaves marijuana as a schedule 1 drug, doctors will continue to stay away from recommending the drug, further limiting the medical market. GreenWave anticipates that as recreational marijuana markets begin to shrink the medical markets, various states will start to merge the regulatory oversight of both the recreational and medical marijuana markets.

    The report stated, “Redundancy in oversight and enforcement mechanisms will be recognized as costly confusing.” The report is careful to highlight that it isn’t predicting the downfall of the medical marijuana market. The group believes that as new, and more targeted drugs become available and doctors become more involved, the medical sector will recalibrate.

    0 3708

    Arcturus Announces Engagement of Financial Advisor for Vertical Farm Project

    VANCOUVER, British Columbia, September 29, 2016 /PRNewswire/ —

    Arcturus Growthstar Technologies Inc. (the “Company” or “Arcturus”) (CSE:AGS) (OTC Pink: AGSTF) is pleased to announce that it has engaged the services of CBO Financial, Inc. as its financial advisor with respect to New Market Tax Credits (NMTC) for a vertical farm project. The NMTC program is a $65 billion federal program designed to incentivize private investment in low-income communities. NMTCs are provided to financial institutions in exchange for equity investments that eligible businesses can use to subsidize project development costs. CBO Financial helps driven organizations, such as Arcturus, to finance facilities that will provide goods and services that benefit populations in need and revitalize communities. Arcturus’ partnership with CBO Financial is both shareholder and capital structure friendly in the sense that the draw of capital is non-dilutive in nature.

    “We are very pleased to have engaged CBO Financial,” says Mr. William Gildea, Arcturus Growthstar Technologies, Inc.’s CEO and Chairman. “CBO Financial is an invaluable resource. We plan to work with CBO Financial to navigate the NMTC qualifying and application process as a means of bringing additional capital to our vertical farming project.”

    Mr. Craig Stanley, CEO and Founder of CBO Financial states, “[t]he CBO Financial team is excited to be selected by Arcturus to assist with securing New Markets Tax Credits for the vertical farm project. CBO has been involved in this program since its inception in 2004 and has received direct awards in six out of thirteen annual rounds totaling $150 million, one of a small number of groups in the U.S. to have received six or more awards. In addition CBO has secured over $500 million in NMTCs for clients. The NMTC program provides 20% to 25% of a project cost in very flexible financing for projects located in low-income communities. We hope this is the first of many projects with Arcturus. For more information see http://www.cbofinancial.com .”

    On behalf of the Board,

    Arcturus Growthstar Technologies Inc.

    William Gildea, CEO & Chairman

    About Arcturus

    The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Arcturus provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land. The contained system provides many other benefits including seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

    The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com which caters to B2B customers is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com which caters to both large and small agriculture green houses and controlled cultivation centers.

    Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

    This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

    ARCTURUS GROWTHSTAR TECHNOLOGIES INC.
    Suite 1518, 1030 West Georgia Street
    Vancouver, British Columbia
    V6E 2Y3

    Contact:
    William Gildea,
    Director
    +1-617-834-9467

    0 2244

    CHEYENNE, Wyo., Sept. 26, 2016 /PRNewswire/ — FBEC Worldwide, Inc. (FBEC) a lifestyle brand company with a focus on Healthy Hemp™ & CBD infused consumer products, is pleased to announce that Amazon.com, Inc. (AMZN) has received FBEC’s WolfShot™ brand of Healthy Hemp™ Energy Shots & is now available for sale on Amazon.com. Wolfshot™ can be purchased here https://www.amazon.com/gp/product/B01IC71UGA.

    This announcement comes after the company announced on September 14, 2016 that it had received a follow up purchase order after a successful test run of WolfShot™ via the Amazon Vendor Express Program. Amazon’s Vendor Express Program allows companies like FBEC Worldwide, Inc. to sell their products directly to Amazon.com, Inc. (AMZN). Amazon takes care of the shipping, promoting & customer service.

    CEO Jeff Greene stated, “Current & potential customers can once again visit Amazon.com & purchase FBEC’s WolfShot™ brand of Healthy Hemp™ Energy Shots. After our previous successful test run with Amazon Vendor Express we look forward to a continued positive reception of our products.”

    About FBEC Worldwide, Inc.

    FBEC Worldwide, Inc. is a lifestyle Brand Company with a focus on Healthy Hemp™ & CBD infused consumer products, both domestic and abroad. We are committed to increasing our market size and scope through the optics of creative marketing and most importantly customer satisfaction. Our growth strategies focus on a number of major initiatives, including unique branding opportunities that will be targeted at key demographic groups and to develop strong community and distributor relationships.

    FBEC Worldwide is currently developing and building Healthy Hemp™ & CBD infused consumer products, focused on strong rates of growth within key fundamental consumer groups. Our company is dedicated to becoming the lead developer of name brand hemp & CBD infused consumer products.

    Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The Company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

    Investor Relations Contact:

    Joe Sirianni
    MIDAM Ventures LLC
    (305) 707-7018
    jsirianni@MidamIr.com
    www.MIDAMIr.com

    An affiliate of MAPH Enterprises, LLC MarijuanaStocks.com | WolfofWeedStreet.com was paid an advertising fee of $60,000 cash & 60 Million Restricted Common shares by FBEC Worldwide Inc. (FBEC) for visual sponsorship of MarijuanaStocks.com | WolfofWeedStreet.com and for visual placement FBEC Worldwide Inc. (FBEC) within written materials. FOR A DURATION OF 5 YEARS BEGINNING JUNE 2015 ending JUNE 2020

    PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

    0 2142

    Ubiquitech Software Announces Name Change to “HempLife Today” Plus Releases Overview of Exciting Plans to Increase Revenues and Continue Company Growth

    DENVER, CO–(Marketwired – Sep 20, 2016) – Ubiquitech Software Corp. ( OTC PINK : UBQU ), CEO and the management of (UBQU) want all shareholders, and the general public, to have an update and overview on the exciting plans the company is implementing in order to continue the upward growth of revenues and the expansion of the CannazALL™ CBD brand.

    The company currently has plans for the following over the next 30 – 120 days, and into 2017, and will be very active in keeping shareholders and the general public updated on a weekly basis…

    Official Name and symbol change to HempLife Today™: Pending the legal requirement filings the company will be known as HempLife Today™, with new symbol (To replace UBQU), also pending. The company believes that the already extensive reach of the HempLife Today™ name, the millions spent on branding, and the ability to leverage this brand into a worldwide powerhouse is the best choice to expand the CannazALL™ CBD product line to a larger market share, and offers greater flexibility and profit potential as the Hemp industry continues to grow.

    New HempLife Today™ logo: Update and freshen the HempLife Today™ logo to add a stronger look to our brand.

    New products: The Company has plans to announce 2-4 new CBD products in 2016.

    New and improved packaging: To increase customer satisfaction, increase public awareness, and also allow for greater retail sales opportunities.

    New proprietary CBD blend: The company is currently developing a new proprietary blend of additional hemp plant products to its CannazALL™ CBD formulas. Making CannazALL™ even more a one-of-a-kind and unique CBD health product, that can only be found in the CannazALL™ brand.

    Introduction of Direct Mail to advertising campaigns. The company is introducing direct mail campaigns to its buyers and subscriber lists, and will be expanding this advertising campaign to larger databases of potential new customers

    CBD GelCap Free Sample: As announced on 9.16.2016…The Company will be BETA testing this offer in October with plans to roll out in November and December. Current data show the Company could add over 50,000- 100,000 new customers annually through this marketing platform.

    Additional Affiliate companies: The Company is currently working with “Content Specific” Sites that can act as Affiliate sellers of CannazALL™ CBD products. Company announced PotGuide.com and ColoradoPotGuide.com were added to its Affiliates earlier this month.

    New CannazALL™ YouTube channel: The Company plans to create a new YouTube channel that will offer instructions and details on CannazALL™ products, dosing, and general information.

    New company, product, and investor video presentations: To be added to the HempLife Today™ Websites and landing pages.

    Improved Delivery: It is the Company goal to ship same day on orders placed before 9Am (MT), and next day on orders placed after 9AM. Company data show that fast shipping results in more frequent, and larger, repeat orders.

    International sales: Expanded delivery into other CBD friendly countries (To be announced in future Press Releases)

    “Going into our third year we are solidifying everything necessary to succeed and be the leader” Said Tim Zorn of HempLife Today™ “Our products are the best they can be, the demand for our products is growing, and our name, brand, and production and delivery systems, are all in place. We are ready to spread the HempLife Today name, and the Cannazall CBD brand, to a bigger and bigger audience”

    “If people think that 2016 has been good so far, just watch what we achieve moving forward” James Ballas of HempLife Today™ “With our new name and symbol change we are ready to expand and grow this company faster than ever before. We feel like a sprinter that’s about to reach full speed, and once we do, there will be no catching us”

    The company is aware that shareholders, and the public, are eager to learn about, and to share, all of the new and exciting plans the company is implementing. Because of this the Company will keep shareholders completely informed on a weekly, and sometimes daily, basis to show the progress of the stated goals in this press release.

    About Ubiquitech (HempLife Today™)
    Ubiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, Direct Response (DRTV) Television, Radio, and traditional marketing, to drive traffic to the new and emerging multi-billion dollar industries like its subsidiary HempLifeToday.com™

    HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It’s popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid, all offered @ www.HempLifeToday.com

    This press release contains forward-looking statements. Words such as “expects”, “intends”, “believes”, and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward- looking statements in order to reflect events or circumstances that may arise after the date of this release.

    0 2447

    American Green Consolidates Office to Phoenix Cultivation Site

    TEMPE, AZ–(Marketwired – Sep 20, 2016) – American Green, Inc. ( OTC PINK : ERBB ) consolidated its primary office with its Phoenix cultivation site to achieve the greatest operational efficiency for both its current and future undertakings. Besides the future grow facility revenue expected at the site, day-to-day engagement with the process has already produced up to three additional locations for duplication. By reducing to dedicated staff who are willing to work building real company value and a willingness to be on location, the company is already experiencing positive growth. The location of the facility will be made public once the signage is up and site-insurance riders are in place. In spite of the current trend to hide such locations, American Green is confident that its security measures will enable the company to be as transparent in its progress as it can be. The goal is to allow shareholder tours throughout the facility beginning sometime in October.

    “After a month of analysis, the Board of Directors and consulting staff have determined that the past plan needed a serious overhaul favoring simplicity and speed,” says David Gwyther, American Green chairman and acting president. “The move comes at a time when both the company and market forces require steadfast, focused effort and commitment to a clear plan designed to insure overall corporate health when the inevitable upswing arrives which will likely benefit those cannabis-connected companies left standing. There are some that over-build because they can, and those that can’t quite achieve lift-off. Our numbers show that for who we are and where we are, this is the best possible scenario,” Gwyther concludes.

    Incorporating fundamental, yet quality building methods with state-of-the-art materials, the site will feature consistency in temperature and humidity, a comprehensive plan for security and hygiene, a limited number of strains targeting primary needs for medicinal marijuana, and an adequate space to expand into the higher-margin extraction business. In a forthcoming update coinciding with the issuance of a Certificate of Occupancy (necessary to begin legal cultivation), American Green’s Phoenix grow facility will publish estimated yields and subsequent revenues based on actual spaces that are built and operational. With the November election and the possibility to legalize ‘recreational’ cannabis, the company believes its current estimates are conservative with a primary goal of operating in the “black” within six months of putting the first plants in their grow medium.

    In other news, The American Green Machine is back. Watch for pending news of the Company’s proprietary next-generation automation system. Demand has caught up with the idea for verified vending of restricted products and the company believes it is positioned to meet and expand on the energized market and growing potential for clients throughout America.

    Be sure to visit the company’s website at www.americangreen.com and sign up for the company’s emails alerts to stay current on news.
    Shareholders and interest holders may also stay current with American Green Updates:

    Twitter: @American__Green (two underscores), or
    Facebook: https://www.facebook.com/americangreenusa

    NOTES ABOUT FORWARD-LOOKING STATEMENTS

    Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission reports and filings. Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.

    About American Green, Corp.

    American Green, Corp., became one of the first publicly traded technology companies in the medical cannabis industry in the world, beginning in 2009, with the introduction of the ZaZZZ machine for automated, age-verifying dispensing of cannabis-based medicines. Now, with over 50,000 individual shareholders, American Green’s mission is to be the cannabis & industrial hemp industry, seed-to sale innovator, leveraging our team of professionals, as well as value-added companies and products – spanning cultivation, manufacturing and extraction, retail, and community outreach. We strive to develop sustainable businesses, while increasing shareholder value, and awareness beyond our industries.

    0 1577

    Hemp, I’d like you to meet Marijuana. She’s going to introduce you to her friend, Cannabis Investor, who will show you life in the fast lane…

    For the past century, hemp has been minding its own business, quietly supplying the world with relatively mundane products like rope, textiles, protein, and vegetable oil. Now, with the wave of medical and recreational marijuana legalization that’s sweeping America, that is changing. Legal cannabis has become the fastest growing market in America. And hemp is now coming along for the wild ride.

    The boom in medical and recreational marijuana has been a big attraction to investors, while at the same time being a serious turnoff for investors and entrepreneurs who don’t want to be involved in the drama and legalities surrounding marijuana. But, with all the attention that medical marijuana is enjoying, it’s becoming clear that many of the medicinal benefits of cannabis can be had without the buzz and the legal worries. Enter cannabidiol (CBD), a cannabinoid extracted from agricultural hemp rather than marijuana.

    Hemp CBD is suddenly getting serious attention from health food entrepreneurs who would never consider investing in marijuana. One such entrepreneur is, Tapio Maki who is the founder of Smart Salt, a reduced sodium mineral salt used in processed foods. Maki’s latest venture, CBD Incorporated, was founded specifically to produce CBD from hemp. The new company is currently raising capital to build a mass production facility in Portugal.

    I sat with Tapio to talk about CBD’s attraction as an alternative investment to medical marijuana. Here’s what he had to say.

    I know you’re dead set against investing in either medical or recreational marijuana. What got you interested in investing in CBD?

    Maki: I follow health food industry news. I kept seeing reports about the medical marijuana “Green Rush.” I didn’t give it much consideration because I don’t want to get involved in the legalities and controversy of marijuana. But then I started to notice reports about CBD, which has many of the same benefits of THC but without the high. CBD can actually be extracted more efficiently from agricultural hemp than from marijuana. After doing some more research, I realized that CBD is in a period of exponential growth that will not slow down any time soon. I believe it’s a better investment than marijuana.

    What were the pros and cons for you of getting into the hemp business?

    The “pros” to me are that I’m certain that the sales of CBD products are going to explode in the coming years. The vast majority of people who are into alternative, natural cures don’t want to be high all the time. I did some math based on industry projections and saw that by 2020, the total global cannabis market – hemp and marijuana-related products – could exceed 100 billion dollars. And, although the vast majority of that is currently for marijuana-based products, interest in CBD’s medical benefits is spreading so quickly that the CBD market is going to become a much more substantial percentage of the cannabis market than it is today.

    The cons are that some investors see the word “cannabis” or they see a pot leaf and they think, “oh, marijuana,” and don’t want to get involved. Even the media keeps lumping hemp CBD into medical marijuana because that’s the hot story. But hemp CBD has nothing to do with marijuana and getting high, and everything to do with health.

    You had originally planned to buy and sell CBD rather than producing it. What changed your mind to consider mass production? And why Portugal?

    After leaving my full time position with Smart Salt, I spent a few years sailing, all the time following the market news. I made made landfall in Portugal in 2013 with plans to continue around the Mediterranean. While I was in Portugal I started talking to my European business associates about CBD and hemp. As it turns out, Portugal is an ideal place to grow hemp. It has a climate very similar to California, abundant sunshine and rain, affordable and highly productive farm land. And CBD extraction is legal. It also turns out that you can’t sell CBD nationwide in the US if it’s not imported. Production became a viable option if we set up shop in Portugal and import to the US.

    Your company is investing heavily in extraction technology. How did you come to the decision to develop your own technology to produce CBD rather than using existing technology?

    For one thing, we plan to produce a very high volume of organic CBD and want environmentally friendly technology that’s tailored to our operation. More importantly, we also plan to be a top name in high volume extraction technology and license our technology to other growers as a major source of revenue. We call our product the ‘Liquid Gold Factory.’ A valuable side benefit is that if the price of CBD starts to go down – which will only happen if more and more companies start producing CBD – we’ll be making up the difference by selling more technology.
    ———

    As part of their fundraising efforts, CBD Inc. is offering CBD resellers a lifetime supply of CBD. Pre-order up to 4 kilos of CBD and get the same amount every year, forever. For more info go to http://www.cbdincorporated.com/get-lifetime-supply-cbd/

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements